folfirinox
Small moleculeexperimental
FOLFIRINOX is a chemotherapy regimen for treatment of advanced pancreatic cancer. It is made up of the following four drugs:FOL – folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-fluorouracil (5-FU); F – fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN – irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX – oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis. — Wikipedia
Clinical trial activity
24 trials · 38 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
18
Phase 3
3
Phase 4
0
Earliest trial started Apr 1, 2014 (NCT02148549)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Catheters · Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 3
- Digestive System Neoplasms · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 3
- Stomach Neoplasms · Phase 2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFOLFIRINOX ↗
Also known as
- firinox
- folfirinox
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05665023 | Phase 2 | Oct 28, 2022 | Yonsei University |
| NCT05132504 | Phase 2 | Jan 1, 2022 | Baylor University, Merck |
| NCT05065801 | Phase 2 | Nov 30, 2021 | Institut Régional du Cancer de Montpellier, University of Montpellier |
| NCT05121038 | Phase 1/Phase 2 (Phase 2) | Oct 20, 2021 | Cend Therapeutics Inc., University of Kansas |
| NCT04990037 | Phase 1 | Jul 31, 2021 | Cantargia AB |
| NCT04897854 | Phase 3 | Apr 22, 2021 | University of Amsterdam |
| NCT04594772 | Phase 2 | Jan 1, 2021 | University of Cincinnati |
| NCT04431258 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2020 | Ability Pharmaceuticals SL |
| NCT04611724 | Phase 2 | Dec 1, 2020 | Boryung Pharmaceutical Company, Green Cross Corporation, University of Ulsan |
| NCT04469556 | Phase 2 | Oct 14, 2020 | Cold Spring Harbor Laboratory, Harvard University, Johns Hopkins University, Memorial Sloan-Kettering Cancer Center, Ontario Institute for Cancer Research, Stand Up To Cancer, University of Toronto |
| NCT04292743 | Phase 1 | May 31, 2020 | ERYtech Pharma, Georgetown University |
| NCT04398927 | Phase 2 | May 1, 2020 | Sun Yat-Sen University |
| NCT05081687 | Phase 3 | Feb 20, 2020 | Albert Einstein Israelite Hospital, Government of Brazil |
| NCT04270929 | Phase 1 | Dec 23, 2019 | Boston University, TriSalus Life Sciences |
| NCT04084496 | Phase 2 | Sep 1, 2019 | Sun Yat-Sen University |
| NCT04130399 | Phase 2 | Jul 1, 2019 | Indiana University |
| NCT03812783 | Phase 2 | Nov 5, 2018 | Sun Yat-Sen University |
| NCT03504423 | Phase 3 | Oct 31, 2018 | Rafael Pharmaceuticals Inc., Wayne State University |
| NCT03563248 | Phase 2 | Aug 10, 2018 | Bristol-Myers Squibb, Harvard University, Lustgarten Foundation, Stand Up To Cancer |
| NCT03484299 | Phase 1 | May 30, 2018 | University of Louisville |
Showing 20 of 24 trials
Page 1 / 2
Organizations
Research & Development (38)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sun Yat-Sen University | Academic/Hospital | 3 | 3 | 1 | 2018 |
| Harvard University | Academic/Hospital | 2 | 1 | 1 | 2018 |
| Stand Up To Cancer | Academic/Hospital | 2 | 0 | 1 | 2018 |
| University of Amsterdam | Academic/Hospital | 2 | 2 | 2 | 2015 |
| Ability Pharmaceuticals SL | For profit | 1 | 1 | 1 | 2020 |
| Albert Einstein Israelite Hospital | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Boryung Pharmaceutical Company | For profit | 1 | 0 | 1 | 2020 |
| Boston University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
| Cantargia AB | For profit | 1 | 1 | 1 | 2021 |
| Cend Therapeutics Inc. | For profit | 1 | 0 | 1 | 2021 |
| Cold Spring Harbor Laboratory | Academic/Hospital | 1 | 0 | 1 | 2020 |
| ERYtech Pharma | For profit | 1 | 0 | 1 | 2020 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Government of Brazil | Government | 1 | 0 | 1 | 2020 |
| Green Cross Corporation | For profit | 1 | 0 | 1 | 2020 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Instituto do Cancer do Estado de São Paulo | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Institut Régional du Cancer de Montpellier | Academic/Hospital | 1 | 0 | 1 | 2021 |
38 organizations
Page 1 / 2